KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Short-term Investments (2016 - 2025)

NovoCure's Short-term Investments history spans 12 years, with the latest figure at $354.1 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 55.52% year-over-year to $354.1 million; the TTM value through Dec 2025 reached $354.1 million, down 55.52%, while the annual FY2025 figure was $354.1 million, 55.52% down from the prior year.
  • Short-term Investments for Q4 2025 was $354.1 million at NovoCure, up from $2.5 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $854.1 million in Q4 2022 and bottomed at $516000.0 in Q2 2023.
  • The 5-year median for Short-term Investments is $452.0 million (2021), against an average of $392.6 million.
  • The largest YoY upside for Short-term Investments was 105736.31% in 2022 against a maximum downside of 99.86% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $807000.0 in 2021, then surged by 105736.31% to $854.1 million in 2022, then decreased by 21.58% to $669.8 million in 2023, then grew by 18.86% to $796.1 million in 2024, then tumbled by 55.52% to $354.1 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Short-term Investments are $354.1 million (Q4 2025), $2.5 million (Q3 2025), and $761.9 million (Q2 2025).